Kymera Therapeutics KYMR EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's EPS (basic)?
- Kymera Therapeutics (KYMR) reported EPS (basic) of -$0.71 in Q1 2026.
- How has Kymera Therapeutics's EPS (basic) changed year-over-year?
- Kymera Therapeutics's EPS (basic) increased by 13.4% year-over-year, from -$0.82 to -$0.71.
- What is the long-term trend for Kymera Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Kymera Therapeutics's EPS (basic) has grown at a 15.3% compound annual growth rate (CAGR), from -$2.09 to -$3.69.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.